Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.75 |
| ▸ | IMPDH2 | P12268 | 7/20 | 0.72 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.72 |
| ▸ | HINT1 | P49773 | 4/20 | 0.70 |
| ▸ | TGM2 | P21980 | 1/20 | 0.70 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.69 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.69 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.65 |
| ▸ | KRAS | P01116 | 3/20 | 0.63 |
| ▸ | CA5A | P35218 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| E626 SCHEMBL17845817 | 1.00 | NT5E (0.75) | NT5EIMPDH2IMPDH1HINT1TGM2 | |
| E626 SCHEMBL20276926 | 0.95 | NT5E (0.83) | NT5EIMPDH2IMPDH1HINT1TGM2 | |
| E626 SCHEMBL13497991 | 0.95 | NT5E (0.83) | NT5EIMPDH2IMPDH1HINT1TGM2 | |
| E626 SCHEMBL18763818 | 0.95 | NT5E (0.83) | NT5EIMPDH2IMPDH1HINT1TGM2 | |
| E626 SCHEMBL18759049 | 0.95 | NT5E (0.83) | NT5EIMPDH2IMPDH1HINT1TGM2 | |
| E626 SCHEMBL9980018 | 0.95 | NT5E (0.83) | NT5EIMPDH2IMPDH1HINT1TGM2 | |
| E626 SCHEMBL20677331 | 0.95 | NT5E (0.83) | NT5EIMPDH2IMPDH1HINT1TGM2 | |
| E626 SCHEMBL21163348 | 0.95 | NT5E (0.83) | NT5EIMPDH2IMPDH1HINT1TGM2 | |
| E626 SCHEMBL21803790 | 0.95 | NT5E (0.83) | NT5EIMPDH2IMPDH1HINT1TGM2 | |
| E626 SCHEMBL18785103 | 0.95 | NT5E (0.83) | NT5EIMPDH2IMPDH1HINT1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119306779-A | R-configuration-containing initial capping oligonucleotide primer and synthesis method thereof | 上海科泽永欣生物科技有限公司 | 2025-01-14 | — | — | CN | claimed |
| CN-119241624-A | Initial capping oligonucleotide primer containing HNA structure and preparation method and application thereof | 上海科泽永欣生物科技有限公司 | 2025-01-03 | — | — | CN | claimed |
| CN-119306779-A | R-configuration-containing initial capping oligonucleotide primer and synthesis method thereof | 上海科泽永欣生物科技有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-119241624-A | Initial capping oligonucleotide primer containing HNA structure and preparation method and application thereof | 上海科泽永欣生物科技有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-117858885-A | Method and device for purifying nucleotide, and hydrophobic reagent and hydrophobic substrate | 国立研究开发法人科学技术振兴机构 | 2024-04-09 | — | — | CN | disclosed |
| US-20230250127-A1 | MODIFIED mRNA 5'-CAP ANALOGS | Nanjing GeneLeap Biotechnology Co., Ltd. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS AG (CH) | 2023-06-15 | — | — | US | disclosed |
| CN-116003496-A | Modified mRNA5' -cap analogues | 南京吉迈生物技术有限公司 | 2023-04-25 | — | — | CN | disclosed |
| WO-2023282245-A1 | METHOD FOR PURIFYING NUCLEOTIDES, DEVICE FOR PURIFYING NUCLEOTIDES, HYDROPHOBIC REAGENT, AND HYDROPHOBIC SUBSTRATE | 国立研究開発法人科学技術振興機構 | 2023-01-12 | — | — | WO | disclosed |
| EP-3904366-A1 | END CAPPED NUCLEIC ACID MOLECULES | Novartis AG (CH) | 2021-11-03 | — | — | EP | disclosed |
| CN-111848712-A | End-capped nucleic acid molecules | 诺华股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20200190132-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-06-18 | — | — | US | disclosed |
| US-10676499-B2 | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA | NOVARTIS AG (CH) | 2020-06-09 | — | — | US | disclosed |
| US-20180002368-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-01-04 | — | — | US | disclosed |
| EP-3233880-A1 | END CAPPED NUCLEIC ACID MOLECULES | Novartis AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016098028-A1 | END CAPPED NUCLEIC ACID MOLECULES | NOVARTIS AG (CH) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250127-A1 | MODIFIED mRNA 5'-CAP ANALOGS | RNGTT, RNMT, NSUN2 | NT5E 338/4885IMPDH2 860/4885IMPDH1 742/4885 |
| US-20230183286-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | RNGTT, NSUN2, NSUN3 | NT5E 106/4885IMPDH2 737/4885IMPDH1 765/4885 |
| US-20200190132-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | RNGTT, NSUN2, NSUN3 | NT5E 106/4885IMPDH2 737/4885IMPDH1 765/4885 |
| US-20180002368-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NSUN2, NSUN3, RNGTT | NT5E 151/4885IMPDH2 763/4885IMPDH1 838/4885 |
| US-10676499-B2 | 3′ end caps, 5′ end caps and combinations thereof for therapeutic RNA | RNGTT, NSUN3, NSUN2 | NT5E 83/4885IMPDH2 724/4885IMPDH1 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.